Early diagnosis in colorectal cancer

Comfortable, fast, reliable early diagnosis

Colo-Check offers a patient-friendly and molecular-based early diagnosis solution in colorectal cancer screening, allowing patients to provide samples without the invasive burden of colonoscopy.

Patients with a positive test result are referred for colonoscopy; in patients with a negative result, the aim is to reduce unnecessary invasive procedures.

Visual representing the Colo-Check testing process in a modern molecular diagnostic laboratory

Dual matrix panel approach

Stool + Serum
G

Stool analysis

Screening of epigenetic cancer traces with a 6-gene panel.

S

Serum analysis

Supportive confirmation from a blood sample with a 3-gene panel.

%90,6

Sensitivity

Performance reported in dual-matrix clinical study data.

%90,0 Dual matrix panel specificity
%90 Strong detection target in early stages
Non Invasive sample collection process
7-8h Optimized laboratory analysis process

Hybrid molecular solution

Dual matrix technology that does not depend on a single sample type

The distinctive aspect of Colo-Check is its ability to simultaneously analyze both stool and serum samples taken from the same patient. This approach helps evaluate epigenetic cancer traces through cross-validation.

Stool analysis only

Provides 80.0% sensitivity and 93.7% specificity data with a 6-gene panel.

Serum analysis only

Provides 75.7% sensitivity and 94.3% specificity data with a 3-gene panel.

Stool + serum panel

Reaches 90.6% sensitivity and 95.0% specificity with the dual matrix approach.

%90

High success rate in the early stage

The survival rate in cancer treatment increases significantly when the disease is diagnosed at an early stage. Colo-Check aims to increase the chance of intervention before cancer shows clinical symptoms or reaches advanced stages.

Clinical studies have stated that Colo-Check maintains approximately 90% sensitivity and 90% specificity performance in Stage I and II tumors.

Comparison

Colonoscopy, Colo-Check and FIT test

Colo-Check stands apart from traditional screening options with its non-invasive structure aimed at increasing patient compliance and its dual-matrix molecular panel performance.

Criteria Colonoscopy Colo-Check FIT
Sensitivity >%95 %90,6 ~%74
Specificity High %95,0 ~%94
Invasiveness Invasive, requires sedation Non-invasive Non-invasive
Patient compliance Low Very high High

*Real data obtained from the clinical study is presented.

ÜTS registration

Medical device registered in the Republic of Turkey Ministry of Health Product Tracking System

ÜTS Registration: Colo-Check is a medical device registered in the Republic of Turkey Ministry of Health Product Tracking System. Start date: 03/07/2025.

Back to Top